Vanguard Group Inc Zentalis Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,654,757 shares of ZNTL stock, worth $21.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,654,757
Previous 4,398,625
28.56%
Holding current value
$21.2 Million
Previous $69.3 Million
66.64%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ZNTL
# of Institutions
148Shares Held
69.8MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$52.3 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$32.1 Million0.62% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$18.1 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$16.9 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.07MShares$11.5 Million3.85% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $214M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...